Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Business Alignment PCL's average EBITDA Per Share Growth Rate was 94.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 27.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 18.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 25.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Business Alignment PCL was 77.00% per year. The lowest was -18.90% per year. And the median was 22.75% per year.
Business Alignment PCL (BKK:BIZ-R) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Business Alignment PCL 5-Year EBITDA Growth Rate Related Terms
BKK:BIZ-R vs ABT, SYK, MDT: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Business Alignment PCL's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Business Alignment PCL 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Business Alignment PCL's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Business Alignment PCL's 5-Year EBITDA Growth Rate falls into.
Business Alignment PCL 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 18.70% mean?
Business Alignment PCL (BKK:BIZ-R) has a 5-Year EBITDA Growth Rate of 18.70% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Business Alignment PCL and its competitors.
Is Business Alignment PCL's 5-Year EBITDA Growth Rate too high?
Business Alignment PCL's current 5-Year EBITDA Growth Rate is 18.70%. Overall, Business Alignment PCL has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Business Alignment PCL's 5-Year EBITDA Growth Rate compare to ABT and SYK?
Business Alignment PCL's 5-Year EBITDA Growth Rate of 18.70% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Business Alignment PCL and its competitors. Business Alignment PCL's current 5-Year EBITDA Growth Rate is 18.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Business Alignment PCL stock overvalued right now?
Business Alignment PCL (BKK:BIZ-R) has a current 5-Year EBITDA Growth Rate of 18.70%. The stock's GF Value™ is ฿5.44, compared to a current price of ฿5.95 — trading 9.4% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 18.70%. Business Alignment PCL's overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Business Alignment PCL (BKK:BIZ-R), the current 5-Year EBITDA Growth Rate is 18.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Business Alignment PCL (BKK:BIZ-R) Overvalued in 2026?
Based on GuruFocus' analysis, Business Alignment PCL stock appears to be overvalued.
The current stock price of ฿5.95 is trading 9.4% above its estimated GF Value™ of ฿5.44.
Key valuation signals for BKK:BIZ-R:
5-Year EBITDA Growth Rate: 18.70%
GF Value™: ฿5.44 vs. price of ฿5.95 (9.4% above fair value)
No single metric tells the full story. See the BKK:BIZ-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Business Alignment PCL is engaged in the distribution and installation of medical equipment for cancer treatment through radiotherapy. The company operates through the sale of medical equipment segment which includes installation, repair, and maintenance. In addition, it also focuses on increasing the efficiency of medical equipment; and Hospital operations (specialized in cancer treatment). The company is a distributor for Radiotherapy products and Brachytheraphy products in Thailand and Cambodia. Geographically, it operates in the region of Thailand.
91GF Score
Get the complete analysis for BKK:BIZ-R
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BIZ-R has been successfully added to your 
